MEDEC slams Canadian classification regulations
This article was originally published in Clinica
The emphasis of the proposed regulations to implement the Canadian risk-based classification system for medical devices is on premarket review, claims the Canadian industry association, MEDEC. The Hearn Report recommendation for improved post-market surveillance has been ignored, says Kevin Murray, director of regulatory affairs and communication at MEDEC.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.